Serum paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, southeast Iran

European Journal of Endocrinology

Volumn 164, Issue 2, 2011, Pages 219-222

  Hashemi, Mohammad ^a   Kordi Tamandani, Dor Mohammad ^b   Sharifi, Nooshin ^b   Moazeni Roodi, Abdolkarim ^c   Kaykhaei, Mahmoud Ali ^a   Narouie, Behzad ^a   Torkmanzehi, Adam ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SISTAN AND BALUCHESTAN   (Iran)

^c ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; ENZYME ASSAY; RISK FACTOR; SPECTROPHOTOMETRY;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IRAN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SPECTROPHOTOMETRY;

EID: 78751517900     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0881     Document Type: Article

References (25)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001 285 2486-2497. (doi:10.1001/jama.285.19.2486)
2. Mackness MI, Arrol S & Durrington PN. Paraoxonase prevents accumulationof lipoperoxides in low-density lipoprotein. FEBS Letters 1991 286 152-154. (doi:10.1016/0014-5793(91)80962-3)
3. Phuntuwate W, Suthisisang C, Koanantakul B, Mackness MI & Mackness B. Paraoxonase 1 status in the Thai population. Journal of Human Genetics 2005 50 293-300. (doi:10.1007/s10038-005-0255-7)
4. Lopez-Flores I, Lacasana M, Blanco-Munoz J, Aguilar-Garduno C, Sanchez-Villegas P, Perez-Mendez OA & Gamboa-Avila R. Relationship between human paraoxonase-1 activity and PON1 polymorphisms in Mexican workers exposed to organophosphate pesticides. Toxicology Letters 2009 188 84-90. (doi:10.1016/j.toxlet.2009.03.010)
5. Jayakumari N & Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. Journal of Clinical Biochemistry and Nutrition 2009 45 278-284. (doi:10.3164/jcbn.08-255)
6. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M & Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991 86 193-199. (doi:10.1016/0021-9150(91)90215-O)
7. Abbott CA, Mackness MI, Kumar S, Boulton AJ & Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology 1995 15 1812-1818.
8. Mohamadin AM, Habib FA & Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome. Pathophysiology 2010 17 189-196. (doi:10.1016/j.pathophys.2009.11.004)
9. Varga E, Seres I, Harangi M, Sztanek F, Asztalos L, Locsey L, Borbas B, Szegedi J, Karpati I & Paragh G. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Disease Markers 2009 26 141-148. (doi:10.3233/DMA-2009-0624)
10. Naderi M, Hashemi M, Komijani-Bozchaloei F, Moazeni-Roodi AK & Momenimoghaddam MA. Paraoxonase and arylesterase activities in patients with pulmonary tuberculosis. Pathophysiology (accepted for publication).
11. Hashemi M, Mehrabifar H, Daliri M & Ghavami S. Adenosine deaminase activity, trypsin inhibitory capacity and total antioxidant capacity in psoriasis. Journal of the European Academy of Dermatology and Venereology 2010 24 329-334. (doi:10.1111/j.1468-3083.2009.03416.x)
12. Young IS & Woodside JV. Antioxidants in health and disease. Journal of Clinical Pathology 2001 54 176-186. (doi:10.1136/jcp.54.3.176)
13. Knight JA. Free radicals: their history and current status in aging and disease. Annals of Clinical and Laboratory Science 1998 28 331-346.
14. Senti M, Tomas M, Fito M, Weinbrenner T, Covas MI, Sala J, Masia R & Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 5422-5426. (doi:10.1210/jc.2003-030648) (Pubitemid 37452748)
15. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR & Aksoy N. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. European Journal of Endocrinology 2010 162 535-541. (doi:10.1530/EJE-09-0732)
16. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Taheri M, Bardestani GR, Zakeri Z, Kordi-Tamandani DM & Ghavami S. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genetics and Molecular Research 2010 9 1735-1741. (doi:10.4238/vol9-3gmr893)
17. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM & Ghavami S. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genetics and Molecular Research 2010 9 333-339. (doi:10.4238/vol9-1gmr728)
18. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D & Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000 101 2510-2517.
19. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P & Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation 1997 99 62-66. (doi:10.1172/JCI119134)
20. Leviev I & James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 516-521. (Pubitemid 30086111)
21. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D & Fuhrman B. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. American Journal of Clinical Nutrition 2000 71 1062-1076.
22. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G & Hendriks HF. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999 147 405-410. (doi:10.1016/S0021-9150(99) 00243-9)
23. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM & Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005 28 385-390. (doi:10.2337/diacare.28.2.385) (Pubitemid 40170944)
24. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M & Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. European Heart Journal 2007 28 857-864. (doi:10.1093/eurheartj/ehl524)
25. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM & Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 108 414-419. (doi:10.1161/01.CIR.0000080897.52664.94)